Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis.

ABSTRACT:

Aims/hypothesis

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used in the treatment of type 2 diabetes, heart failure and chronic kidney disease. Their role in the prevention of diet-induced metabolic deteriorations, such as obesity, insulin resistance and fatty liver disease, has not been defined yet. In this study we set out to test whether empagliflozin prevents weight gain and metabolic dysfunction in a mouse model of diet-induced obesity and insulin resistance.

Methods

C57Bl/6 mice were fed a western-type diet supplemented with empagliflozin (WDE) or without empagliflozin (WD) for 10 weeks. A standard control diet (CD) without or with empagliflozin (CDE) was used to control for diet-specific effects. Metabolic phenotyping included assessment of body weigh

SUBMITTER: Radlinger B 

PROVIDER: S-EPMC9947060 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature